CKLSF (CK Life Sciences International Holdings) Current Deferred Revenue: $0.0 Mil (As of Dec. 2025)


CKLSF CK Life Sciences International Holdings Inc CKLSF
39 GF Score
Price $0.09
GF Value $0.11
! 5 Warning Signs
View Full Analysis

What is CK Life Sciences International Holdings Current Deferred Revenue?

CK Life Sciences International Holdings CKLSF +28.57% 39 Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus rates CKLSF with a GF Score™ of 39/100 and a GF Value™ of $0.11. The stock has 5 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

CK Life Sciences International Holdings's current deferred revenue for the quarter that ended in Dec. 2025 was $0.0 Mil.

CK Life Sciences International Holdings Current Deferred Revenue Related Terms

CK Life Sciences International Holdings Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for CK Life Sciences International Holdings's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CK Life Sciences International Holdings Current Deferred Revenue Chart

CK Life Sciences International Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CK Life Sciences International Holdings Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CKLSF
39GF Score
CK Life Sciences International Holdings Inc CKLSF
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $0.0 Mil mean?
CK Life Sciences International Holdings (CKLSF) has a Current Deferred Revenue of $0.0 Mil as of Dec. 2025. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on CK Life Sciences International Holdings and its competitors.
Is CK Life Sciences International Holdings' Current Deferred Revenue too high?
CK Life Sciences International Holdings' current Current Deferred Revenue is $0.0 Mil. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Current Deferred Revenue compare to VRTX and REGN?
CK Life Sciences International Holdings' Current Deferred Revenue of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current Current Deferred Revenue is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Current Deferred Revenue of $0.0 Mil. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Current Deferred Revenue is $0.0 Mil. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Current Deferred Revenue is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?

Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued. The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.

Key valuation signals for CKLSF:

  • Current Deferred Revenue: $0.0 Mil
  • GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
  • GF Score™: 39/100 with 5 warning signs

No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CK Life Sciences International Holdings Business Description

Other Exchanges 00775:Hong Kong
Address 2 Dai Fu Street, Tai Po Industrial Estate, Tai Po, Hong Kong, HKG
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score

Get the complete analysis for CKLSF

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.09
Price
$0.11
GF Value